BioCentury
ARTICLE | Clinical News

Immunocore reports Phase I/II data for uveal melanoma candidate

June 1, 2018 6:21 PM UTC

Immunocore Ltd. (Abingdon, U.K.) reported data from 19 evaluable patients with metastatic uveal melanoma in the Phase I portion of the Phase I/II IMCgp100-102 trial showing that IMCgp100 (ImmTAC-gp100) led to two partial responses, plus four minor responses. Median duration of response was 30.6 weeks. One-year progression-free survival (PFS) and overall survival (OS) rates were 66% and 74%, respectively. Median OS has not been reached at a median follow-up of 15.9 months. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The Phase II portion of the open-label trial is enrolling about 150 patients to receive once-weekly 68 μg IMCgp100. Enrollment in the Phase II portion is slated to be completed in September 2019...